Funding and Grants

Current Funding Opportunities

MCW Cancer Center Pilot Funding Program►OPEN NOW Highly Promising NCI R01 Submissions

Now available, NCI grant support resources from the MCW Cancer Center.

To get started, please make a formal request by completing the form located here.  For more information, contact Kitty Marquardt, Research Program Manager, at kmarquardt@mcw.edu.

National Cancer Institute (NCI)

Open AllClose All
  The Pancreatic Cancer Detection Consortium (U01) (Deadline: 9/21/17 or 4/6/18)

The Pancreatic Cancer Detection Consortium (U01)

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma.

The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units.

The Units will undertake studies on the following areas:

  • Identification and testing of biomarkers measurable in bodily fluids for early detection of PDAC or its precursor lesions;
  • Determine which pancreatic cysts are likely to progress to cancer;
  • Develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC;
  • Conduct biomarker validation studies; and
  • Collect longitudinal biospecimens for the establishment of a biorepository.

All Units are expected to participate in collaborative activities with other Units and share ideas, specimens and data within the Consortium.

Applications due September 21, 2017 OR April 6, 2018

  Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25) (Deadline: 9/25/17 or 1/25/18)

Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25)

Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, as well as the cause and reduction of cancer health disparities in accordance with the overall mission of the NCI

Applications due September 25, 2017 or January 25, 2018

  Limited Competition: Lasker Clinical Research Scholars Transition Award (R00) (Rolling Deadline: 9/25/17-1/7/18)

Limited Competition: Lasker Clinical Research Scholars Transition Award (R00)

The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Rolling Deadline: Applications due September 25, 2017-January 7, 2018

  Advancing Interventions to Improve Medication Adherence (R01) (Deadline: 10/5/17)

Advancing Interventions to Improve Medication Adherence (R01)

This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes and Centers. This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement. Primary outcomes of the research can include a patient self-report of medication adherence, but must also at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.). In addition, applications are encouraged to include a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered.

Applications due October 5, 2017

  Advancing the Science of Geriatric Palliative Care (R01) (Deadline: 10/5/17)

Advancing the Science of Geriatric Palliative Care (R01)

This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings.

This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.

Applications due October 5, 2017

  Assay Development and Screening for Discovery of Chemical Probes or Therapeutic Agents (R01) (Deadline: 10/5/17)

Assay Development and Screening for Discovery of Chemical Probes or Therapeutic Agents (R01)

Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.

Stages of discovery research covered by this FOA include:

  1. Assay development;
  2. Primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens);
  3. Hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

Applications due October 5, 2017

  Biology of Lung, and Head and Neck Preneoplasias (R01 - Clinical Trial Not Allowed) (Deadline: 10/5/17)

Biology of Lung, and Head and Neck Preneoplasias (R01 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.

Applications due October 5, 2017

  Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01) (Deadline: 10/5/17)

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Applications due October 5, 2017

  Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01) (Deadline: 10/5/17)

Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)

The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. These small molecules could be further developed into stand-alone immunotherapeutics or synergistic partners for existing therapies, or as chemical probes for the discovery and validation of novel targets involved in anti-tumor immunity. Investigators from multiple scientific disciplines (immuno-oncology, tumor biology, screening technology, medicinal chemistry, and pharmacology) are encouraged to establish collaborative teams to discover and develop novel small molecule immunomodulators for cancer therapy.

This FOA encourages the design of research projects that utilize the following phases of discovery research:

  1. Assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads;
  2. Screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches);
  3. Hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and
  4. Hit-to-lead optimization.

Applications due October 5, 2017

  End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) With Serious Illnesses (R01) (Deadline: 10/5/17)

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) With Serious Illnesses (R01)

The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 - 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Applications due October 5, 2017

  Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01) (Deadline: 10/5/17)

Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Applications due October 5, 2017

  Gene Fusions in Pediatric Sarcomas (R01) (Deadline: 10/5/17)

Gene Fusions in Pediatric Sarcomas (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics.

Applications due October 5, 2017

  High Throughput Screening (HTS) to Discover Chemical Probes (R01) (Deadline: 10/5/17)

High Throughput Screening (HTS) to Discover Chemical Probes (R01)

This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in:

  1. Discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and
  2. Discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.

Applications due October 5, 2017

  Integration of Individual Residential Histories into Cancer Research (R01) (Deadline: 10/5/17)

Integration of Individual Residential Histories into Cancer Research (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

Applications due October 5, 2017

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01) (Deadline: 10/5/17)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Applications due October 5, 2017

  Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01) (Deadline: 10/5/17)

Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01)

The main objective of this Funding Opportunity Announcement (FOA) is to promote application of nutrigenetics and/or nutrigenomics approaches to nutrition research through collaborative interaction among nutrition researchers and experts in omics technologies.

Applications due October 5, 2017

  Population Health Interventions: Integrating Individual and Group Level Evidence (R01) (Deadline: 10/5/17)

Population Health Interventions: Integrating Individual and Group Level Evidence (R01)

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Applications due October 5, 2017

  Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R01) (Deadline: 10/5/17)

Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R01)

This Funding Opportunity Announcement (FOA) encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs.

This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes.

Applications due October 5, 2017

  Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01) (Deadline: 10/5/17)

Research on the Mechanisms and/or Behavioral Outcomes of Multisensory Processing (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications that elucidate the mechanisms and/or behavioral outcomes of multisensory processing, the integration or processing of at least two distinct types of sensory input as defined by distinct receptor-type transduction, neural pathways and cognate perceptual quality. Specifically, multiple sensory inputs may include the major traditional modalities of hearing, vision, taste, smell, balance, and touch. Additional submodalities of body senses include but are not restricted to thermosensation, body position and proprioception, pain, itch, and general visceral sensation.

This FOA encourages research grant applications investigating multisensory processing in perception or other behavioral and social outcomes and/or the mechanisms underlying multisensory processing in the context of the described specific areas of research interests from the participating NIH Institutes, Centers, and Offices (ICOs). The FOA is intended to encourage basic, behavioral, and/or clinical research projects examining the interactions between other neural systems, such as cognitive, affective, or motor processes, and multiple sensory modalities. Multisensory research applications that do not align with the specific areas of research interests described below by the participating NIH ICOs should be submitted to the parent R01 FOA, PA-13-302.

Applications due October 5, 2017

  Research on the Health of Transgender and Gender Nonconforming Populations (R01) (Deadline: 10/5/17)

Research on the Health of Transgender and Gender Nonconforming Populations (R01)

This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.

Applications due October 5, 2017 (standard dates apply)

  Synthetic Biology for Engineering Applications (R01) (Deadline: 10/5/17)

Synthetic Biology for Engineering Applications (R01)

This Funding Opportunity Announcement (FOA) invites applications to conduct research to advance the understanding and application of synthetic biology for human health. It will support 1) the development of innovative tools and technologies in synthetic biology and 2) their application in biomedical research and human health. An integrative research plan based on collaborations of synthetic biologists with computational scientists, cell biologists, engineers, and/or physician scientists is strongly recommended. Early stage investigators in Synthetic Biology are especially encouraged to apply.

Applications due October 5, 2017

  The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01) (Deadline: 10/5/17)

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R01)

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death.

Applications due October 5, 2017

  Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01) (Deadline: 10/5/17)

Using Small Molecules and Molecular Genetics to Identify Novel Targets and Mechanisms Contributing to Tumor Immune Evasion (R01)

The purpose of this funding opportunity (FOA) is to stimulate research on the identification of new and novel targets and mechanisms involved in tumor immune evasion, which may be amenable to analysis by small molecules, pharmacological, or molecular genetics approaches. A specific focus of this FOA is to encourage cross disciplinary collaborations between immunologists, cell biologists, medicinal chemists, pharmacologists, and molecular biologists.

Applications due October 5, 2017

  Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01) (Deadline: 10/10/17)

Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 10, 2017

  Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21) (Deadline: 10/10/17)

Intervening With Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21)

This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Applications due October 10, 2017

  Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21) (Deadline: 10/10/17)

Predicting Behavioral Responses to Population-Level Cancer Control Strategies (R21)

The goal of this funding opportunity announcement (FOA) is to facilitate research to identify individual influences on the effectiveness of population-level strategies that target cancer-related behaviors. We seek to encourage collaborations among scientists with expertise in health policy research and implementation, as well as investigators in scientific disciplines that have not traditionally conducted cancer or policy research, such as: psychological science (e.g., social, developmental); affective and cognitive neuroscience; judgment and decision-making; consumer behavior and marketing; organizational behavior; sociology, cultural anthropology; behavioral economics; linguistics; and political science. 

Applications due October 10, 2017

  US Tobacco Control Policies to Reduce Health Disparities (R01) (Deadline: 10/11/17)

US Tobacco Control Policies to Reduce Health Disparities (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

Application due October 11, 2017

  US Tobacco Control Policies to Reduce Health Disparities (R21) (Deadline: 10/11/17)

US Tobacco Control Policies to Reduce Health Disparities (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

Application due October 11, 2017

  Expanding Genome Integrity Assays to Population Studies (U01) (Deadline: 10/13/17)

Expanding Genome Integrity Assays to Population Studies (U01)

The funding opportunity announcement (FOA) will support development and pilot testing of assays, such as DNA repair capacity or mutation detection, that will facilitate the wider use of genome integrity investigation in epidemiological and population studies. Applications should aim to expand understanding of environmental diseases or exposure effects with the additional knowledge that genome integrity assays will bring. Transdisciplinary research should focus on a common research theme related to the role of environmental exposures.

NCI is interested in applications focused on DNA repair assays that relate to cancer risk and outcomes. As appropriate, the project should also facilitate integration of laboratory and human research to collectively increase understanding of the contribution of genome integrity variation and environmental factors to understand risk, pathogenesis, prevention, or resistance to disease.

Applications due October 13, 2017

  Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplements and Natural Products (Admin Supp) (Deadline: 10/15/17)

Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplements and Natural Products (Admin Supp)

The reproducibility and comparability of dietary supplement research is enhanced through rigorous analytical characterization of key experimental materials. The publication of analytical methods which have been thoroughly validated for specific, precise, accurate, and sensitive quantitative determination of chemical constituents of dietary supplements therefore makes critical contributions to the rigor and reproducibility of biomedical research.

This FOA will build on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of relevant quantitative analytical methods. The methods proposed for validation must be used to identify and quantify chemical constituents (active or marker chemical compounds, adulterants, contaminants) or metabolites thereof in experimental reagents, raw materials, and/or clinical specimens (for example urine or plasma samples). Methods must have been developed or utilized in fulfillment of the active parent grant’s specific aims.

Candidate constituents for quantitative method validation studies may include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.

Applications due October 15, 2017

  Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33) (Deadline: 10/16/17)

Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33)

This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed either through PA-12-064, or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

Applications due October 16, 2017

  Advancing Interventions to Improve Medication Adherence (R21) (Deadline: 10/16/17)

Advancing Interventions to Improve Medication Adherence (R21)

This funding opportunity announcement (FOA) is being issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes. This FOA encourages Exploratory/Developmental Research Project Grant (R21) applications for research and development of interventions to significantly improve medication adherence in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS). A well-articulated theoretical or conceptual framework is key for applications encouraged under this announcement.

Applicants should demonstrate the feasibility of collecting multi-modal data on the targets of the intervention including: a patient self-report of medication adherence, at least one non-self-report measure of medication adherence (e.g., pharmacy refill records, electronic monitoring, etc.), and a relevant health outcome or biomarker (e.g., blood pressure, viral load in HIV-infected individuals, cholesterol levels, HbA1c) that is expected to be affected by changes in the targeted adherence behavior. For diseases without identified biomarkers, inclusion of a clinical assessment (e.g., a medicine blood level, diagnostic interview or an independent clinician rating of the symptoms and behaviors) may be considered. Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism. For example, long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted under this mechanism should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.

Applications due October 16, 2017

  Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed) (Deadline: 10/16/17)

Biology of Lung, and Head and Neck Preneoplasias (R21 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) seeks applications investigating mechanistic and biological aspects of preneoplasia leading to lung, and head and neck (HN) cancers. Despite improved therapies and a deeper molecular understanding of lung and HN cancers, these tumors remain a major health problem in the United States and globally. While molecular markers of early injury to the aerodigestive epithelial field have been found, relatively little is known about the molecular mechanisms that initiate these preneoplasias and drive their progression to invasive cancer. A functional understanding of the key molecular changes involved in the formation and progression of lung and HN preneoplasias will enhance our knowledge of oncogenic progression and accelerate development of effective preventive and therapeutic strategies.

Applications due October 16, 2017

  End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) With Serious Illnesses (R21) (Deadline: 10/16/17)

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) With Serious Illnesses (R21)

The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 - 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Applications due October 16, 2017

  Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03) (Deadline: 10/16/17)

Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03)

This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

Applications due October 16, 2017

  Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21) (Deadline: 10/16/17)

Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

Applications due October 16, 2017

  Integration of Individual Residential Histories into Cancer Research (R21) (Deadline: 10/16/17)

Integration of Individual Residential Histories into Cancer Research (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

Applications due October 16, 2017

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03) (Deadline: 10/16/17)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Applications due October 16, 2017

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21) (Deadline: 10/16/17)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery

Applications due October 16, 2017

  Mechanisms of Cancer and Treatment-Related Symptoms and Toxicities (R21) (Deadline: 10/16/17)

Mechanisms of Cancer and Treatment-Related Symptoms and Toxicities (R21)

This Funding Opportunity Announcement (FOA) invites innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioral, and sociocultural factors that contribute to cancer and treatment related symptoms and toxicities throughout the cancer care trajectory. Data from the preliminary studies would be used to validate and extend the findings in larger cohort studies and/or test novel, mechanistically-driven interventions via the R01 funding mechanism. Of particular interest is to gain new insights about these factors, either alone or in combination, in minority, underserved, the elderly, and pediatric and young adult populations. Specifically, the FOA aims to identify, describe, and quantify these factors associated with acute and chronic cancer and treatment related symptoms and toxicities.

Applications due October 16, 2017

  Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21) (Deadline: 10/16/17)

Pilot and Feasibility Clinical and Translational Research Studies in Digestive Diseases and Nutrition (R21)

This FOA issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Cancer Institute, and the Office of Dietary Supplements (ODS) of the National Institutes of Health encourages pilot and feasibility clinical and epidemiological research studies of new therapies or means of health promotion and prevention of digestive and liver diseases and nutritional disorders associated with digestive and liver diseases

Applications due October 16, 2017

  Population Health Interventions: Integrating Individual and Group Level Evidence (R21) (Deadline: 10/16/17)

Population Health Interventions: Integrating Individual and Group Level Evidence (R21)

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Applications due October 16, 2017

  Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03) (Deadline: 10/16/17)

Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03)

This Funding Opportunity Announcement (FOA) invites applications to conduct research on the effects of alcohol-related public policies on health, economic, and social behaviors and outcomes. The purpose of the FOA is to advance understanding of public policy pertaining to alcohol as a tool for improving public health and welfare. The NIAAA has developed the Alcohol Policy Information System (APIS) as a resource for researchers conducting studies in this area; studies that make use of the information available through APIS are particularly encouraged. Research supported by this FOA includes, but is not necessarily limited to, studies examining the effects of alcohol-related public policies on health-related behaviors and outcomes, evaluations of public policies as tools for improving public health, and research to advance methods and measurement used in studying relationships between alcohol-related public policies and health-related behaviors and outcomes.

Applications due October 16, 2017

  Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21) (Deadline: 10/16/17)

Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21)

This Funding Opportunity Announcement (FOA) encourages applications to conduct research on the effects of public policies on health-related behaviors and outcomes associated with alcohol, marijuana, and other substances. The purpose of the FOA is to advance understanding of how public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol and other drugs. This FOA is intended to support innovative research to examine policy effects that have the potential to lead to meaningful changes in public health. Research projects that may be supported by this FOA include, but are not necessarily limited to: causal analyses of the effects of one or multiple public policies; evaluations of the effectiveness of specific public policies as tools for improving public health through their effects on alcohol-, marijuana-, and other substance-related behaviors and outcomes; and research to advance methods and measurement used in studying relationships between public policies and alcohol-, marijuana-, and other substance-related behaviors and outcomes.

The R21 Exploratory/Developmental Grant supports exploratory and developmental research projects that are expected to generate subsequent R01 (Research Project Grant) applications by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. This FOA for R21 applications is not intended to support projects designed to achieve incremental advances in established research areas.

Applications due October 16, 2017

  Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33) (Deadline: 10/16/17)

Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33)

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.

Applications due October 16, 2017

  Research on the Health of Transgender and Gender Nonconforming Populations (R21) (Deadline: 10/16/17)

Research on the Health of Transgender and Gender Nonconforming Populations (R21)

This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.

Applications due October 16, 2017 (standard dates apply)

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) (Deadline: 10/16/17)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at:

  1. Testing new theories and conceptual frameworks;
  2. Developing and evaluating novel strategies to improve cancer-related health behaviors;
  3. Investigating multi-level and multi-behavioral approaches; and
  4. Utilizing innovative research designs, methodologies, and technologies.

The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Applications due October 16, 2017

  The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21) (Deadline: 10/16/17)

The Interplay of Cell Death Pathways in Cancer Cell Survival and Resistance to Therapy (R21)

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in naïve and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving naïve and drug resistant cancer cells toward effective cell death.

Applications due October 16, 2017

  Consortium Linking Oncology with Thrombosis (CLOT) (U01) (Deadline: 10/23/17)

Consortium Linking Oncology with Thrombosis (CLOT) (U01)

The purpose of this FOA is to establish a program which will provide support for the collaborative efforts of oncologists and coagulation/vascular experts to identify, further develop, and implement advances in thrombosis and hemostasis research into practice for cancer patients.

Applications due October 23, 2017

  Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers (U01) (Deadline: 10/24/17)

Consortium on Translational Research in Early Detection of Liver Cancer: Translational Research Centers (U01)

This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of several Translational Research Centers (TRCs, to be supported by this U01 FOA) and a Data Management and Coordinating Center (DMCC, to be supported a companion U24 FOA, RFA-CA-17-028).

Applications due October 24, 2017

  Consortium on Translational Research in Early Detection of Liver Cancer: Data Management and Coordinating Center (U24) (Deadline: 10/24/17)

Consortium on Translational Research in Early Detection of Liver Cancer: Data Management and Coordinating Center (U24)

This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of a Data Management and Coordinating Center (DMCC, to be supported by this U24 FOA) and several Translational Research Centers (TRCs, to be supported by the companion U01 FOA, RFA-CA-17-025).

Applications due October 24, 2017

  Coordinating Center for the Consortium of Translational Research in Early Detection of Liver Cancer (U24) (Deadline: 10/24/17)

Coordinating Center for the Consortium of Translational Research in Early Detection of Liver Cancer (U24)

This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of a Data Management and Coordinating Center (DMCC, to be supported by this U24 FOA) and several Translational Research Centers (TRCs, to be supported by the companion U01 FOA, RFA-CA-17-025). 

Applications due October 24, 2017

  Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01) (Deadline: 10/24/17; LOI due 30 days prior)

Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment (U01)

The purpose of this initiative is to establish an Academic-Industrial Partnership Program to develop new and/or validate existing technologies, methods, and assays for the capture and quantification of tumor associated cells, DNA, RNA, or exosomes in body fluids of patients with early stage disease or those at high risk; as well as distinguishing cancer from benign disease; or aggressive from indolent cancers. The precompetitive alliances with industry will harmonize and validate technologies, methods and assays associated with liquid biopsies.

Applications due October 24, 2017; LOI due 30 days prior.

  Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24) (Deadline for Renewals: 10/26/17)

Limited Competition: A Data Resource for Analyzing Blood and Marrow Transplants (U24)

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to solicit the Center for International Blood and Marrow Transplant Research (CIBMTR) a limited competition application for the continued support of the Data Resource for Analyzing Blood and Marrow Transplants program. The support for this FOA is to ensure the continued availability of the CIBMTR database as a resource to investigators, transplant physicians, and healthcare policy-makers.

Applications due October 26, 2017 (RENEWALS ONLY)

  Neural Regulation of Cancer (R01) (Deadline: 10/26/17)

Neural Regulation of Cancer (R01)

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

Applications due October 26, 2017

  Neural Regulation of Cancer (R21) (Deadline: 10/26/17)

Neural Regulation of Cancer (R21)

This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer elements, which together will advance current understanding of the nervous system contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

Applications due October 26, 2017

  KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research (Deadline: 10/27/17)

KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research

The KRAS Fellowship provides $100,000 in research funding over a two-year period. The grant term begins on July 1, 2017, and concludes on June 30, 2019. In addition to the research grant, Fellows are provided with $5,000 in travel support plus housing to visit FNLCR.

During the grant term, Fellows are given guest researcher status at FNLCR and are trained and granted access to onsite technology to support their funded research. They also receive support from the RAS Initiative team in planning experimental approaches for their funded project, mentorship from the RAS Initiative leadership and opportunities to participate in scientific lab meetings and workshops and to forge collaborations with other RAS researchers.

Fellows also attend the Pancreatic Cancer Action Network's Annual Scientific Meeting (scheduled for August 17-20, 2017, and dates to be determined in 2018 and 2019). This meeting brings together grant recipients and members of the organization’s Scientific and Medical Advisory Board for research feedback, knowledge exchange, mentorship and collaboration. Support for travel to the annual meeting is provided separate from the Fellowship grant.

Applications due October 27, 2017

  Clinical and Epidemiological Research on Chronic Disease in the Caribbean (R01-Clinical Trial Not Allowed) (Deadline: 11/15/17)

Clinical and Epidemiological Research on Chronic Disease in the Caribbean (R01-Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support US-Caribbean collaborative research to develop or extend cohort or surveillance studies on chronic disease in the Caribbean region that are aligned with existing publicly available US datasets. The intent is for these cohorts or datasets to be used for ongoing comparative research to better understand the health of Caribbean immigrant populations in the US.       

Applications due November 15, 2017

  Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) (Deadline: 11/15/17; LOI due 30 days prior)

Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on fusion oncoproteins in childhood cancers. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them.

The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting.

Applications due November 15, 2017; LOI due 30 days prior

  Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54) (Deadline: 11/15/17)

Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on fusion oncoproteins in childhood cancers. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP):

Recommendation E.
Intensify research on the major drivers of childhood cancers:
Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting.

Applications due November 15, 2017

  Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01)

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Applications due November 27, 2017

  Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21)

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Applications due November 27, 2017

  Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Applications due November 27, 2017

  Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Applications due November 27, 2017

  New Informatics Tools and Methods to Enhance US Cancer Surveillance and Research (UG3/UH3) (Deadline: 11/30/17)

New Informatics Tools and Methods to Enhance US Cancer Surveillance and Research (UG3/UH3)

The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA seeks applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration cancer registry data and to expand the data items collected. Applications must be built on partnership with U.S. population-based central cancer registries (a partnership must involve at least two different registries). Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.

Applications due November 30, 2017

  Notice of Intent to Publish a Funding Opportunity Announcement for ‘Programs to Increase Diversity among Individuals Engaged in Health Related Research’ (PRIDE) Summer Institutes (R25)/(U24) (Deadline: FOA December 2017 (expected); Due date March 2018)

Notice of Intent to Publish a Funding Opportunity Announcement for ‘Programs to Increase Diversity among Individuals Engaged in Health Related Research’ (PRIDE) Summer Institutes (R25)/(U24)

The National Heart, Lung, and Blood Institute intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for the Programs to Increase Diversity among Individuals Engaged in Health Related Research (PRIDE) Summer Institutes. The PRIDE Summer Institutes programs aim to enhance the diversity of the biomedical, behavioral and clinical research workforce through provision of research education and mentoring experiences for junior faculty from underrepresented backgrounds, at NHLBI-funded summer institutes across the nation.

This Notice is being provided to allow potential applicants sufficient time to develop responsive applications. The FOA is expected to be published in December 2017 with an application due date in March 2018 and will utilize the R25 mechanism. Details of this planned FOA are provided below.

FOA Expected Release Date: December 2017 with a due date of March 2018

  Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R01 Clinical Trial Not Allowed) (Deadline: 12/4/17)

Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R01 Clinical Trial Not Allowed)

The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

Applications due December 4, 2017

  Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R21 Clinical Trial Not Allowed) (Deadline: 12/4/17)

Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R21 Clinical Trial Not Allowed)

The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

Applications due December 4, 2017

  Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) (Deadline: 1/9/18)

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." 

Applications due January 9, 2018

  Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) (Deadline: 1/9/18)

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

This Funding Opportunity Announcement (FOA) invites U01 application for projects aimed at identifying best practices to improve case ascertainment of hereditary cancers, with the goal of improving prevention and detection.

Applications due January 9, 2018

  Cardiovascular and Pulmonary Research on E-Cigarettes (R01) (Deadline: 1/16/18)

Cardiovascular and Pulmonary Research on E-Cigarettes (R01)

The purpose of this funding opportunity announcement (FOA) is to stimulate research on cardiovascular and pulmonary physiologic and health effects of electronic cigarette (e-cigarette) exposure. This FOA invites applications addressing the effects of e-cigarettes on the cardiovascular and pulmonary systems, alone or in combination. Studies involving clinical populations, animal models and/or cell preparations would all be considered responsive. Research may examine the effects of the whole e-cigarette aerosol or of individual components or constituents. Research may also examine where aerosols, components, or constituents deposit in the airways and resulting heart and/or lung consequences.

Applications due January 16, 2018

  Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01) (Deadline: 1/31/18)

Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01)

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigan’s National Addiction & HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Research’s (ICPSR) website.

Applications due January 31, 2018

  Tobacco Regulatory Science (R01) (Deadline: 2/13/18; LOI due 30 days prior)

Tobacco Regulatory Science (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Applications due February 13, 2018 with an LOI due 30 days prior

  Tobacco Regulatory Science (R21) (Deadline: 2/13/18; LOI due 30 days prior)

Tobacco Regulatory Science (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. 

Applications due February 13, 2018 with an LOI due 30 days prior

  Biological Comparisons in Patient-Derived Models of Cancer (U01) (Deadline: 3/7/18)

Biological Comparisons in Patient-Derived Models of Cancer (U01)

The purpose of this FOA is to encourage applications wherein similarities and differences in the underlying biological mechanisms that drive cancer phenotype and response to perturbations between two or more patient-derived models of cancer originating from a common patient sample are delineated and compared.

Applications due March 7, 2018

National Institutes of Health (NIH)

Open AllClose All
  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

  Expanding Genome Integrity Assays to Population Studies (U01) (Deadline: LOI by 8/30/17; to NCI by 10/13/17)

Expanding Genome Integrity Assays to Population Studies (U01)

The funding opportunity announcement (FOA) will support development and pilot testing of assays, such as DNA repair capacity or mutation detection, that will facilitate the wider use of genome integrity investigation in epidemiological and population studies. NCI is particularly interested in studies that include data with cancer related phenotypes and tools that facilitate such investigation.

*Limited Submission

Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

Please submit LOI by August 30, 2017 so we can decipher if science is scientifically distinct.

Deadline for Application to NCI: October 13, 2017

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  Educational Grants (Bayer AG; Bayer USA Foundation) (Deadlines: 8/8/17 for Oncology; 10/1/17 for Generic Education)

Educational Grants (Bayer AG; Bayer USA Foundation)

The goal of the contributions and educational grants initiatives is to promote the general prevention and treatment of disease and illness. Bayer strategically focuses its funding in support of research, education and patient support. As a commitment to improving patient care and providing valuable information to the medical and broader healthcare community, Bayer HealthCare will accept the following grant requests:

  1. Healthcare professional education
  2. Patient advocacy and Consumer education programs (e.g., disease-state education and awareness, screenings, camps, etc.)

Areas of Support:

  • Dermatology
  • Radiology
  • Hematology-Hemophilia
  • General Medicine (Pulmonology/Cardiology/Infectious Disease/Non-Cystic Fibrosis Bronchiectasis)
  • Neurology
  • Women's Health

Oncology:

  • Advanced Prostate Cancer
  • Colorectal Cancer
  • Gastrointestinal Stromal Tumor
  • Hepatocellular Carcinoma
  • Thyroid Cancer

Applications due August 8, 2017 (Oncology); October 1, 2017 (Generic Education)

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Independent Grants for Learning & Change (IGL&C): The Evolving Standard of Care for Patients with HR+, HER2- Breast Cancer (Deadline: 9/20/17)

Independent Grants for Learning & Change (IGL&C): The Evolving Standard of Care for Patients with HR+, HER2- Breast Cancer

It is our intent to support continuing professional development programs (CME/CE) for medical oncologists, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the care and treatment of patients with HR+, HER2- breast cancer.

Recent advances in the treatment of metastatic breast cancer have resulted in a shift in the treatment paradigm of patients with HR+, HER2- breast cancer. As the standard of care is changing, proposed programs should focus on increasing the awareness and understanding of the clinical evidence for combination therapy over aromatase inhibitor (AI) monotherapy.

Application due September 20, 2017

  Lung Cancer Research Program (LCRP): Career Development Award (Deadline: 10/4/17)

Lung Cancer Research Program (LCRP): Career Development Award

The goal of the FY17 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. To be considered for funding, application for the FY17 LCRP Career Development Award must address at least one of the seven areas of emphasis listed in the grant opportunity announcement.

Applications due October 4, 2017

  Lung Cancer Research Program (LCRP): Idea Development Award (Deadline: 10/4/17)

Lung Cancer Research Program (LCRP): Idea Development Award

The goal of the FY17 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer. To be considered for funding, application for the FY17 LCRP Idea Development Award must address at least one of the seven areas of emphasis listed in the grant opportunity announcement.  

Applications due October 4, 2017

  Lung Cancer Research Program (LCRP): Investigator-Initiated Translational Research Award (Deadline: 10/4/17)

Lung Cancer Research Program (LCRP): Investigator-Initiated Translational Research Award

The goal of the FY17 LCRP is to eradicate deaths from lung cancer to better the health and welfare of military Service members, Veterans, their families, and the American public. As such, the LCRP will support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, and treatment for the control and cure of lung cancer.

Applications due October 4, 2017

  Lung Cancer Research Program (LCRP) Translational Research Partnership Award (Deadline: 10/4/17)

Lung Cancer Research Program (LCRP) Translational Research Partnership Award

The FY17 LCRP Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications.

This award supports the development of translational research collaborations between two independent, faculty level (or equivalent) investigators to address a central problem or question in lung cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. In addition, one partner in the collaboration is strongly encouraged to be an active duty Service member or Federal employee from a military treatment facility, Department of Defense (DoD) laboratory, or a Department of Veterans Affairs (VA) medical center or research laboratory. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged but not required. At least one member of the partnership must have experience either in lung cancer research or lung cancer patient care. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism. Observations that drive a research idea may be derived from a laboratory discovery, population- based studies, or a clinician's firsthand knowledge of patients and anecdotal data.

The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, members of the partnership should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.

Applications due October 4, 2017

  Peer Reviewed Cancer Research Program (PRCRP) - Career Development Award (Deadline: 10/4/17)

Peer Reviewed Cancer Research Program (PRCRP) - Career Development Award

To be considered for funding, applications for the FY17 PRCRP Career Development Award must address at least one of the FY17 PRCRP Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, or ovarian cancer will not be accepted. The FY17 PRCRP Topic Areas are listed below.

  • Bladder cancer
  • Melanoma and other skin cancers
  • Colorectal cancer
  • Mesothelioma
  • Immunotherapy
  • Lymphoma
  • Neuroblastoma
  • Kidney cancer
  • Pancreatic cancer
  • Listeria vaccine for cancer
  • Pediatric brain tumors
  • Stomach cancer
  • Cancer in children, adolescents, and young adults (new for FY17)

Applications due October 4, 2017

  Childhood Cancer Research Seed Grants (Deadline: LOI due 10/19/17; Applications due 3/15/18)

Childhood Cancer Research Seed Grants

The Foundation invites applications for its seed grant program, which provides funding to conduct innovative, cutting edge investigations, with preferences going toward less common childhood cancers. In addition, more projects that focus on Opsoclonus-Myoclonus Syndrome (OMS) will be considered.

The Foundation is interested in principal investigators who will join it in taking risks, pushing for new solutions, and harnessing the transformative power of science in their research in the following broad areas:

  • Mechanisms of Disease
  • Genetics
  • Preclinical Models
  • Biomarkers and Surrogate Markers
  • Prognostic Factors
  • Diagnosis
  • Innovative Clinical Therapeutic Trials
  • Minimal Residual Disease Detection
  • Treatment
  • Supportive Care and Prevention
  • Amelioration of Long-Term Effects of Therapy

By seeking answers and adding to the body of knowledge in pediatric cancer research, The Pablove Foundation will make an impact on the lives of children who are affected by childhood cancer.

LOI Due October 19, 2017, Applications due March 15, 2018

  Request for Proposals: Awards for Established Investigators - Pilot Awards (Deadline: 10/21/17)

Request for Proposals: Awards for Established Investigators - Pilot Awards

MRA announces its eighth annual RFP, soliciting translational research grant applications. The RFP calls for ideas that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment.

Potentially transformative pilot studies. Pilot proposals are not required to contain extensive preliminary data, but must articulate a clear hypothesis and translational goals.

Applications due October 21, 2017 (Multiple applications will be accepted from a single institution, provided that each application has a different PI and represents a distinct hypothesis.)

  Accelerate Clinical Trials Grant (Free to Breathe) (Deadline: 10/28/17)

Accelerate Clinical Trials Grant (Free to Breathe)

This funding opportunity is focused on research to investigate strategies and interventions to increase clinical trial accrual to therapeutic lung cancer clinical trials. The goal is to fund pilot research projects that will investigate novel strategies to improve accrual of patients with lung cancer to therapeutic clinical trials by at least 50% within a defined healthcare facility, system or community. Project aims must have specific strategies focused on increasing accrual to cancer trials of lung cancer. Proposals must have a clear vision about how the pilot project, if successful, can be an expanded to other institutions for validation of the intervention or strategy. The intent of Free to Breathe is to fund projects that will be reproducible and implementable to a wider community as well as applicable to other cancer types.

Applications due October 28, 2017

  AST TIRN Faculty Development Research Grants (Deadline: 11/1/17)

AST TIRN Faculty Development Research Grants

The purpose of these grants is to promote the careers of young independent investigators. This grant allows the investigator to expand on preliminary research findings that will become the basis for individual research or career development awards from the NIH, VA, or equivalent agencies.

Applications due November 1, 2017

  Annual DeGregorio Foundation Award for Cancers of the Esophagus and Stomach (Deadline: 11/7/17)

Annual DeGregorio Foundation Award for Cancers of the Esophagus and Stomach

The foundation is pleased to announce the 8th annual funding opportunity for gastroesophageal malignancies. The foundation seeks to promote and facilitate collaborative research on the pathogenesis, early diagnosis, and treatment of upper gastrointestinal malignancies. It supports high quality, innovative, and transformative translational and bench research to improve the understanding of the biology of these diseases, identification of potential novel therapeutic targets, or in the development and evaluation of novel biomarkers for early diagnosis and treatment. Pre-clinical research, basic mechanistic studies, genomic/epigenomic studies, as well as epidemiologic studies may also be supported.

Applications due November 7, 2017

  Advanced Clinical Research Award (ACRA) (Deadline: 11/16/17)

Advanced Clinical Research Award (ACRA)

The Advanced Clinical Research Award (ACRA) is a topic-specific competition designed to support physician-scientists committed to performing original, clinical cancer research in an area not currently funded. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects.

Applications due November 16, 2017

  MRA Established Investigators Academic-Industry Partnership Awards (Deadline: 11/17/17)

MRA Established Investigators Academic-Industry Partnership Awards

The MRA is soliciting proposals that address the gap in translational science, i.e., turning scientific discoveries into tools and/or treatments for high risk individuals and melanoma patients. Successful proposals will offer the potential for translational development that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment..

Full Proposal due November 17, 2017
*Multiple applications will be accepted from a single institution, provided that each application has a different PI and represents a distinct hypothesis.

  Scientific Scholar Award (Marsha Rivkin Center for Ovarian Cancer Research) (Deadline: 12/1/17)

Scientific Scholar Award (Marsha Rivkin Center for Ovarian Cancer Research)

The Rivkin Center Scientific Scholar Award is intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. Research funding for ovarian cancer is comparatively low, which discourages talented laboratory scientists and physicians from directing their careers toward ovarian cancer. The Scientific Scholar Award provides the funds for the best and brightest minds to have an opportunity to begin a career in ovarian cancer research.

Applications due December 1, 2017

  Interventional Oncology/Immuno-Oncology Research Grant / SIO Research Grant (Deadline: 12/15/17)

Interventional Oncology/Immuno-Oncology Research Grant / SIO Research Grant

The Society of Interventional Oncology / Immuno-Oncology Research Grant, generously sponsored by Biocompatibles UK Ltd., is designed to fund research evaluating immune stimulation of interventional oncologic therapies, combination approaches to improve clinical outcome, and an improved understanding of the underlying mechanisms as to how our different therapies influence both adaptive and innate immunity, as well as underlying inflammation and tumorigenesis.

Application due December 15, 2017

  Lung Cancer Discovery Award (Deadline: 12/21/17)

Lung Cancer Discovery Award

Investigators with projects that focus on understanding the impact of lung cancer in women are encouraged to apply, areas of interest include:

  • Novel examination of tumor testing
  • Pilot Studies examining new treatment options
  • Lung Cancer in Never-Smokers
  • Patient Centered Outcomes, Patient Engagement and Health Services Research


Projects are expected to have a direct impact on early detection/treatment methods or provide a clear conceptual or experimental foundation for future development. The preference is for studies that are likely to result in patient benefit in the near future.

Applications due December 21, 2017

  MRA Team Science Awards (Deadline: 1/9/18)

MRA Team Science Awards

Awards for team science are designed to foster a collaborative research process and promote transformational melanoma research advances with the potential for rapid clinical translation. Multidisciplinary teams will receive funding to support projects with the potential to lead to transformative advances in prevention, detection, diagnosis, staging and/or treatment of melanoma.

Team Science Awards have a collaborative and multidisciplinary emphasis, involving meaningful collaboration between participants. LOIs must include a description of the nature of and rationale for the proposed collaboration, the specific role of all PIs and the Young Investigator, and synergistic opportunities derived from the team proposed. Evidence of prior productive collaborations between members of the team is also useful.

Full Proposal due January 9, 2018

  Collaborative Pediatric Cancer Research Awards Program: Grant Funding Opportunity In Pediatric Oncology - Independent Investigator and Consortium Grant (Deadline: 1/10/18)

Collaborative Pediatric Cancer Research Awards Program: Grant Funding Opportunity In Pediatric Oncology - Independent Investigator and Consortium Grant

Collaborative Pediatric Cancer Research Awards Program members include Rally Foundation, Bear Necessities, Arms Wide Open Childhood Cancer Foundation, and The Truth 365, national non-profit organizations dedicated to eliminating childhood cancer through innovative research in pediatric oncology. Members of the Collaboration may choose to co-fund or individually fund an applicant.

Rally funds research in the following areas:

  • Under-studied cancer types
  • Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials
  • Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
  • Quality of life and survivorship research proposals

Full Proposal due January 10, 2018

  Discovery Grant (Deadline: 1/10/18)

Discovery Grant

The ABTA Discovery Grants are intended to encourage the development of new approaches to the diagnosis and treatment of brain tumors. By providing funding through its Discovery Grants, the ABTA seeks to support high-risk/high-impact projects with the potential to change current diagnostic or treatment paradigms for adult and pediatric brain tumor care. These grants specifically encourage novel research by allowing researchers to conduct the early scientific studies needed to secure additional/future funding for their projects. Additionally, investigators from sciences outside traditional biological fields are encouraged to apply. The development of new diagnostic and therapeutic approaches advances the understanding and treatment of brain tumors, and increases the potential for improving, extending and ultimately saving the lives of those living with a brain tumor diagnosis.

Full Proposal due January 10, 2018

  CONquer canCER Now Award (Deadlines: LOI by 9/7/17; Full Proposal by 12/7/17)

CONquer canCER Now Award

By specifically targeting promising early-career scientists and providing critically needed "seed" money for innovative projects, Concern Foundation supports development of the next generation of cancer researchers and thus promotes progress in understanding cancer biology and improved approaches to cancer.

**Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology**

Concern will not fund clinical trials, cancer epidemiology, or behavioral studies.

LOI due September 7, 2017

Full Proposal due December 7, 2017

  Hope Funds for Cancer Research-Postdoctoral Fellowship (Pre-Applications Deadline: 9/15/17; Full application Deadline: 1/14/18)

Hope Funds for Cancer Research-Postdoctoral Fellowship

The Hope Funds for Cancer Research is offering fellowships to postdoctoral scientists who propose to work on highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS.

Pre-Applications due September 15, 2017; Application due January 14, 2018

  Stand Up To Cancer (SU2C) Dream Team Translational Research Grant (Deadline: LOI by 9/5/17; Invited Full Proposal by 1/16/18)

Stand Up To Cancer (SU2C) Dream Team Translational Research Grant

The Stand Up To Cancer Dream Team Translational Research Grant will fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.

The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.

LOI due September 5, 2017

Invited full proposals due January 16, 2018

  AACR NextGen Grants for Transformative Cancer Research (Deadline: 1/8/18; LOI due 9/22/17)

AACR NextGen Grants for Transformative Cancer Research

The proposed research must represent a highly innovative approach to a major contemporary challenge in cancer research. The funded projects must have the potential to lead to groundbreaking discoveries in the field, and transform our understanding of the tumorigenesis process and/or our ability to treat, detect, or prevent cancer. The research can be in any area of basic, translational, or clinical science.

Applications due January 8, 2018; LOI Deadline: September 22, 2017

  Prostate Cancer Research Program (PCRP)- Health Disparity Research Award (Deadline: 9/28/17)

Prostate Cancer Research Program (PCRP)- Health Disparity Research Award

The Health Disparity Research Award supports new ideas based on innovative concepts or methodologies for health disparity research with the potential to make an important contribution toward eliminating death from prostate cancer and enhancing the well-being of men impacted by the disease. Studies proposed for this award mechanism are expected to improve the understanding of and/or address factors that contribute to differences in the disease experience across populations, ultimately contributing to eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship.

Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity. The PCRP is interested in research that addresses all different aspects that contribute to health disparity in prostate cancer, including social, cultural, and/or biological contributors. Because of the emphasis on innovation, the inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required.

Any preliminary, unpublished data provided should be from the Principal Investigator (PI) or a member(s) of the research team.

Applications due September 28, 2017

  Breast Cancer Research Program (BCRP) - Breakthrough Award - Levels 3 and 4 (Pre-Application Deadline: 9/29/17)

Breast Cancer Research Program (BCRP) - Breakthrough Award - Levels 3 and 4

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:

  • Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.
  • Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. The current Program Announcement discusses Funding Levels 3 and 4.

The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

  • Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
  • Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. Human clinical testing is required. PIs are expected to have experience in successfully leading large-scale projects

Pre-Application Due: September 29, 2017

  Breast Cancer Research Program (BCRP) - Distinguished Investigator Award (Pre-Application Deadline: 9/29/17)

Breast Cancer Research Program (BCRP) - Distinguished Investigator Award

The BCRP Distinguished Investigator Award enables established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer. These individuals should be exceptionally talented researchers who have shown that they are leaders in their field(s) through extraordinary creativity, vision, and productivity. The Principal Investigator (PI) is expected to have a renowned reputation as a researcher who has made groundbreaking contributions to advancing his/her field. He/she should have demonstrated success at forming and leading effective partnerships and collaborations. Through his/her distinguished record of research and leadership, the PI should demonstrate the potential to make unique and significant advances in breast cancer.

Pre-Application Due: September 29, 2017

  Breast Cancer Research Program (BCRP) - Innovator Award (Pre-Application Deadline: 9/29/17)

Breast Cancer Research Program (BCRP) - Innovator Award

Considering the current breast cancer landscape and the BCRP's vision to end breast cancer, each FY17 BCRP Innovator Award application must address one or more of the following overarching challenges. Alternatively, with adequate justification, applications may identify and address another overarching challenge related to the breast cancer landscape. Justification must be provided in the application.

  • Prevent breast cancer (primary prevention)
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers
  • Conquer the problems of overdiagnosis and overtreatment
  • Identify what drives breast cancer growth; determine how to stop it
  • Identify why some breast cancers become metastatic
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge (recurrence); determine how to prevent recurrence
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
  • Eliminate the mortality associated with metastatic breast cancer

Pre-Application Due: September 29, 2017

  Milstein Research Scholar Awards for Melanoma/Non-Melanoma Skin Cancer (Deadline: 10/1/17)

Milstein Research Scholar Awards for Melanoma/Non-Melanoma Skin Cancer

This award supports basic science and clinical research for melanoma/non-melanoma skin cancer by gifted investigators in the early phases of their careers. This program offers funds to foster the career development of a young investigator working in the field of dermatology or cutaneous biology. The aim of the program is to provide bridge support for young investigators.

The individual must have a strong career goal within the field of dermatology and be dedicated to the furtherance of knowledge concerning melanoma/non-melanoma skin cancer. The research must be focused on new discoveries in the basic or translational medical sciences that impact the understanding or treatment of melanoma/non-melanoma skin cancer.

Applications due October 1, 2017

  Administrative Supplements for Research on Dietary Supplements (Admin Supp) (Deadline: 10/15/17)

Administrative Supplements for Research on Dietary Supplements (Admin Supp)

This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention.

Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention.

Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease.

This FOA will not support new clinical trials.

Applications due October 15, 2017

  Research Grants for Independent Investigators - Research Scholar Grants (ACS) (Deadline: 10/16/17)

Research Grants for Independent Investigators - Research Scholar Grants (ACS)

With a primary focus on beginning investigators, the American Cancer Society's Extramural Grants Program seeks to support innovative cancer research across a wide range of disciplines to meet critically important needs in the control of cancer.

Applications due October 16, 2017

  RFA: Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families (ACS) (Deadline: 10/16/17)

RFA: Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families (ACS)

This RFA provides funding for investigators performing pilot and exploratory research studies whose purpose is to test interventions, develop research methodologies, and explore novel areas of research in palliative care of cancer patients and their families. A condition of funding is a clearly defined plan as to how the investigator will use the results of the project to develop larger, extramurally funded research projects.

This RFA is limited to applications that focus on palliative care research projects for seriously ill cancer patients and their families in three specific areas:

  1. Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses;
  2. Studying methods of improving communication between adults living with serious illness, their families and their health care providers;
  3. Evaluating models and systems of care for patients living with advanced illness and their families.

Applications due October 16, 2017

  RFA: The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services (ACS) (Deadline: 10/16/17)

RFA: The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services (ACS)

A call for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. New health public policy initiatives such as the new federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by healthcare systems, insurers, payers, communities, practices, and patients.

Application is due October 16, 2017

  RFA: Understanding, Preventing, and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers (ACS) (Deadline: 10/16/17)

RFA: Understanding, Preventing, and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers (ACS)

Research towards the prevention, early detection, reduction and/or management of life-altering and/or outcome-limiting side-effects of checkpoint inhibitor therapy is needed. A critical gap in management of irAEs is early identification of which patients are at greatest risk for various irAEs, which patient features are indicative of irAEs, the time course of clinical manifestation and if prevention strategies can limit side-effects without diminishing efficacy

Application is due October 16, 2017

  Understanding, Preventing, and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers (Deadline: 10/16/17)

Understanding, Preventing, and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers

To facilitate research focused on prevention, risk, early detection, and management of short- and long-term immune-related adverse events (irAEs) associated with FDA-approved or late-stage development checkpoint cancer immunotherapies for melanoma and other cancers.

Applications due October 16, 2017

  Metabolomic Data Analysis and Interpretation Tools (U01) (Deadline: 10/20/17)

Metabolomic Data Analysis and Interpretation Tools (U01)

The goal of this cooperative agreement Funding Opportunity Announcement (FOA) is to address key challenges in analyzing and interpreting metabolomics data by developing novel tools to facilitate metabolomics data analysis and interpretation. Specifically, successful awardees will develop new or enhanced computational approaches or tools that facilitate metabolomics data analysis, interpretation, and integration. Generalizable, scalable, and portable solutions appropriate for scientists with limited expertise in informatics are particularly encouraged. Projects are not intended to supplement ongoing metabolomics analyses, but to provide tools for broader use by the biomedical research community.

Components of Participating Organizations
This Funding Opportunity Announcement (FOA) is developed as a Common Fund initiative through the NIH Office of the NIH Director, Office of Strategic Coordination. All NIH Institutes and Centers participate in Common Fund initiatives. The FOA will be administered by the National Cancer Institute (NCI/NIH), on behalf of the NIH.

Applications due October 20, 2017

  Symptom Management for Patients with Advanced Illness – (Cycle 2 2017) (Deadline: 10/25/17)

Symptom Management for Patients with Advanced Illness – (Cycle 2 2017)

The Patient-Centered Outcomes Research Institute (PCORI) is launching this research initiative to generate needed scientific evidence to aid patients, caregivers, and providers in decision making about the clinical options for symptom management in advanced illness. PCORI seeks to fund multiple high-quality clinical studies comparing evidence-based pharmacological and non-pharmacological treatments for the range of symptoms experienced by patients with advanced illness. This PCORI Funding Announcement (PFA) focuses specifically on the following symptoms:

  • Pain
  • Fatigue
  • Dyspnea
  • Insomnia
  • Anorexia/cachexia
  • Nausea/vomiting
  • Depression and/or anxiety

This PFA is targeted toward advanced illnesses such as (but not limited to) advanced heart failure, advanced cancer, chronic obstructive pulmonary disease, end-stage liver and kidney disease, or neurodegenerative diseases.

Applications due October 25, 2017

  Clinic and Laboratory Integration Program (CLIP) Grants (LOI Deadline: 11/1/17)

Clinic and Laboratory Integration Program (CLIP) Grants

The Cancer Research Institute funds research aimed at furthering the development of immunological approaches to the diagnosis, treatment, and prevention of cancer. The Institute's mission is to bring effective immune system-based therapies to cancer patients sooner.

CRI offers its Clinic and Laboratory Integration Program (CLIP) Grants to qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The program supports basic, pre-clinical, and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic.

LOI is due November 1, 2017

  Translational Research Program (Deadline: 11/15/17)

Translational Research Program

The Translational Research Program puts you on the bench-to-bedside fast track when it comes to finding better treatment and cures for leukemia, lymphoma and myeloma. The Leukemia & Lymphoma Society funds new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application.

Applications due November 15, 2017

  Breast Cancer Research Program (BCRP) - Breakthrough Award - Levels 1 and 2 (Pre-Application Deadline: 11/21/17)

Breast Cancer Research Program (BCRP) - Breakthrough Award - Levels 1 and 2

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:
Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.

The goal is to pursue innovative research that is translational in nature, and that has the potential to impact childhood cancer diagnosis and treatment.

The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

  • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required.
  • Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation.

Pre-Application Due: November 21, 2017

  Breast Cancer Research Program (BCRP) - Era of Hope Scholar Award (Pre-Application Deadline: 11/21/17)

Breast Cancer Research Program (BCRP) - Era of Hope Scholar Award

The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.

The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the "best and brightest" in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer.

Pre-Application Due: November 21, 2017

  Foundation for Women's Cancer Prize For Outstanding Gynecologic Cancer Researcher (Deadline: 11/27/17)

Foundation for Women's Cancer Prize For Outstanding Gynecologic Cancer Researcher

This new Prize for Outstanding Gynecologic Cancer Researcher is a $10,000 prize, awarded to an individual in recognition of his or her outstanding contributions to research improving the care of women with gynecologic cancer. The selected awardees will have made important contributions that improve gynecologic cancer patient care, including the early detection, treatment or prevention of gynecologic cancers. The award will be made to the individual rather than his/her institution.  Individuals can apply for this prize or nominators can propose potential candidates by filling out the application on the following page.

Applications due November 27, 2017

  Appendix A: NASA Research and Technology Development to Support Crew Health and Performance in Space Exploration Missions (Deadline for Step 2: 12/5/17)

Appendix A: NASA Research and Technology Development to Support Crew Health and Performance in Space Exploration Missions

Ground-based research in the use of archived irradiated tissue samples or those from ongoing studies should address the following specific research focus areas (only those in cancer listed below):

 

  1. Examination of available tissue samples for evidence of dose-dependent, common pathway activation (e.g., inflammation) across tissues that address multiple risk areas (cancer, CNS, and cardiovascular disease) and inform identification of biomarkers and radioprotective countermeasures.

    Deliverables: Research results supporting identification of cross-risk biomarkers and countermeasures.
     
  2. Examination of available tissues from chronically irradiated animals, including bone marrow and/or blood samples, to evaluate immune and hematopoietic function using clinically relevant measures.

    Deliverables: Research evidence supporting risk characterization of potential deficits to the hematopoietic/immune system induced by chronic radiation exposure.
     
  3. Advanced molecular characterization of high-mass, high-energy (HZE) and mixed-field radiation-induced tumors, supporting the extrapolation of animal data to human datasets to inform cancer morbidity and mortality projections, and biomarker and countermeasure identification. Characterization of tumors of the lung, colon, stomach, breast, ovary, bladder, and liver are of interest for this topic.

    Deliverables: Research results supporting extrapolation of animal data to humans, as required to inform cancer morbidity and mortality projections, and biomarker and countermeasure identification.

Proposals due:

  • Step1: September 12, 2017
  • Step 2: December 5, 2017
  Appendix B: NASA Human Research Program Omnibus Opportunity (Deadline for Step 2: 12/5/17)

Appendix B: NASA Human Research Program Omnibus Opportunity

To expedite progress in various research areas in a short period of time, NASA is requesting proposals for short-term investigations or technology development projects that provide innovative approaches to any of the risks and associated knowledge gaps contained in the Integrated Research Plan (IRP) of the Human Research Program (HRP). Risks and gaps identified in the IRP included, but are not limited to, the following:

  1. Exploration Medical Capability (includes risks posed by inflight medical conditions such as renal stones, and bone fracture)
  2. Human Factors and Behavioral Performance (includes risks such as behavior, cognitive, or psychiatric disorders; sleep disorders; failures in interpersonal communication, leadership, or training; or problems caused by inadequate design of habitats, robotics, or human-computer interaction)
  3. Human Health Countermeasures (includes measures for addressing proper nutrition, cardiac health, bone health, and altered immune response)
  4. Space Radiation (includes risks posed by radiation such as cancer, and damage to the central nervous system)

Proposals due:

  • Step1: September 12, 2017
  • Step 2: December 5, 2017
  Desmoid Tumor Research Foundation (Deadline: 1/12/18)

Desmoid Tumor Research Foundation

The Desmoid Tumor Research Foundation, Inc. (“DTRF”) funds research that will advance the current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure. DTRF is the only foundation in the world dedicated to facilitating and funding research for a cure for desmoid tumors.

We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research. Research proposals with additional sources of funding support are particularly desirable. Researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF’s future grant review cycle, as well as to exert best efforts to attend the annual fall International DTRF Desmoid Tumor Research Workshop

Applications due January 12, 2018

  Fanconi Anemia Research Fund (Deadline: 2/2/18)

Fanconi Anemia Research Fund

The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities:

  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders.
  • To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life.
  • To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.

Applications due February 02, 2018

  Adenoid Cystic Carcinoma Research Foundation (Deadline: Continuous)

Adenoid Cystic Carcinoma Research Foundation

Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.

Deadline continuous

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline: Continuous)

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline: Continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

  Women's Cancer Research Grants (Deadline: Continuous)

Women's Cancer Research Grants

The FWC continues to seek additional funding to support expanded research priorities. Of special importance is increased funding for cervical, uterine, primary peritoneal, vaginal and vulvar cancer research. Additionally, the Foundation is seeking funding for a series of new types of research opportunities:

  • Post-Doctoral Fellowship grants: These grants are intended to attract and support promising young scientists and clinician/scientists to ensure the next generation of skilled researchers dedicated to gynecologic cancer research.
  • Career Development Awards: These grants are similar to the NIH CDA, K series awards, and are awarded to applicants who wish to further develop their careers in gynecologic cancer biomedical, behavioral or clinical research
  • Paired grants: Junior investigators would join with senior investigators for grants lasting two to three years.
  • Innovative grants: These grants would provide funding for creative and imaginative research projects that show promise for significant breakthroughs, but have not been sufficiently advanced or developed to receive support through traditional funding channels.
  • Extension of the current, highly successful stimulus or “seed” grant program to include all gynecologic cancers, and the opportunity for competitive renewals at the conclusion of the one-year research grant.

Deadline continuous

Top